IMCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Immunocore Holdings PLC (IMCR) is not a strong buy at this time for a beginner investor with a long-term strategy. While there are some positive catalysts such as analyst upgrades and potential long-term biotech sector recovery, the technical indicators are neutral to bearish, and the financial performance shows declining net income and EPS. The lack of significant trading signals or recent news further supports a hold recommendation.
The technical indicators for IMCR are neutral to bearish. The MACD is slightly positive but contracting, RSI is neutral at 38.626, and moving averages suggest a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 32.229, with key support at 31.006 and resistance at 33.451.
UBS upgraded the stock to Buy with a price target of $55, citing improving biotech fundamentals and strong performance expected in
Morgan Stanley raised the price target to $40, reflecting optimism in small-to-mid cap biotech outperformance.
Financial performance shows a significant decline in net income (-102.03% YoY) and EPS (-100% YoY).
No recent news or significant trading activity from insiders or hedge funds.
Technical indicators do not suggest a strong upward trend.
In Q3 2025, revenue increased by 29.22% YoY to $103.69M, but net income dropped significantly by -102.03% YoY to -$177K. EPS also fell by -100% YoY to 0, and gross margin slightly improved to 99.51%.
Analyst sentiment is mixed but improving. UBS upgraded the stock to Buy with a $55 price target, while Morgan Stanley raised the target to $40 but maintained an Equal Weight rating. Analysts expect a recovery in biotech fundamentals and strong performance in 2026.
